VIENNA (MedPage Today) -- Survival failed to improve in patients with heavily treated non-small cell lung cancer who received sorafenib, but the drug did offer advantages in disease control and other outcomes, investigators reported here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com
Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2012/09/targeted-agent-turns-in-mixed-results.html
No comments:
Post a Comment